G. Klebe, TOWARD A MORE EFFICIENT HANDLING OF CONFORMATIONAL FLEXIBILITY IN COMPUTER-ASSISTED MODELING OF DRUG MOLECULES, Perspectives in drug discovery and design, 3, 1995, pp. 85-105
Several computational search techniques are described to map the confo
rmation space of flexible organic molecules. A vast multiplicity of ge
ometries is produced that has to be minimized according to a particula
r energy function. Comparative studies on a nine-membered cyclic lacta
m are taken as an example. They show that thoroughly tailored search c
onditions can obtain roughly comparable search efficiencies. Out of th
e vast multiplicity of geometrically possible and computationally acce
ssible conformers, only a limited number will be of relevance for the
problem under consideration. In ligand design for drug discovery, a re
lative energy ranking determined on isolated conformers is only of lim
ited use for the selection of biologically relevant conformers. This i
s due to an unsatisfactory transferability of energy scales between di
fferent energy functions and the strong modulation of conformational e
nergies of isolated molecules once exposed to a structured molecular e
nvironment. A knowledge-based approach, using torsion-angle libraries
as retrieved for common fragments in small-molecule crystal structures
, allows one to map more efficiently the biologically relevant part of
conformation space. The relevance of these libraries for the conditio
ns at the binding pocket of a protein is evidenced by experimental dat
a. Sets of well-distributed conformers can be used to compare differen
t drug molecules binding to common targets. Such comparisons reveal ne
w modes of structural superposition of the molecules and consideration
of their physicochemical properties leads to interesting pharmacophor
e hypotheses. They indicate possible binding geometries at the recogni
tion site of a protein and highlight the structural similarities and d
ifferences that correlate with changes in the biological properties. C
omparisons of GP IIb/IIIa receptor antagonists and of thrombin inhibit
ors are discussed.